Abstract: The present invention provides a method of treating and preventing the common cold and associated secondary illnesses in a human subject, when the common cold is caused by viruses. The method comprises applying to the nasal passages of the human subject at ambient temperature, an effective amount of a pharmaceutical preparation comprising povidone-iodine (PVP-I) at a concentration of greater than 0.10% w/v and less than 2.5% in which at least 50% of the PVP-I is not associated with liposomes or other particulate carriers.
Abstract: Reduced-ethanol perfume compositions according to the invention comprise specific combinations of acrylates/VA copolymer and acrylates copolymer in an aqueous base or delivery vehicle. The perfume compositions according to the invention are easy to manufacture and provide an aqueous perfume composition that preserves aromatic integrity (intensity, duration and range), even in emulsion form. The most advantageous use of compositions of the invention are as parfums, eau de parfums, eau de toilettes, and colognes. However, the invention may also find use in many types of fragranced products, such as those used on the skin and hair of humans or animals, in cleaning products of all types, in air deodorizers, air fresheners, and more.
Abstract: The present disclosure relates to a hair care compositions comprising at least two or more polysaccharides, one or more monomeric polyols, and water. The compositions may also include polyglycerol esters of fatty acids. The hair care compositions are particularly useful in methods for imparting durable styling or shaping benefits and/or frizz control to hair.
Abstract: The present invention relates to an aqueous cosmetic composition based on a bicarbonate salt, said composition being stabilized by a pair of particular gelling agents, and also to the cosmetic use thereof as a deodorant. It also relates to a roll-on deodorant containing this composition.
Abstract: A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the pharmaceutical composition.
Type:
Grant
Filed:
January 4, 2017
Date of Patent:
February 9, 2021
Assignee:
BIAL-Portela & C.A., S.A.
Inventors:
Teöfilo Cardoso de Vasconcelos, Ricardo Jorge dos Santos Lima, Rui Cerdeira de Campos Costa
Abstract: This disclosure describes a lyoprotectant matrix, compositions including the lyoprotectant matrix and methods for storing a liquid biospecimen using the lyoprotectant matrix. Generally, the lyoprotectant matrix includes a non-woven web having fibers having, as components, at least one lyoprotective carbohydrate and at least one polymer. The matrix further possesses an apparent pore size of 0.1 ?m to 500 ?m.
Type:
Grant
Filed:
November 11, 2016
Date of Patent:
February 2, 2021
Assignee:
Regents of the University of Minnesota
Inventors:
Alptekin Aksan, Morwena Jane V. Solivio, Marcus Kramer, Rebekah Less
Abstract: The present invention provides a technique that allows a pharmaceutical composition, preferably for external use, containing luliconazole or the like to contain luliconazole or the like at a high concentration, and suppresses the precipitation thereof over time. The present invention uses a polyethylene glycol having an average molecular weight of 380 to 420 represented by a formula HOCH2(CH2OCH2)nCH2OH (where n is an integer), ethanol, benzyl alcohol, lactic acid, propylene carbonate, and acetone in combination with the luliconazole or the like.
Abstract: The present invention relates generally to therapeutic articles comprised of carbonaceous blend textile materials comprising yarns having about 25 to 100 weight % carbonaceous fiber and about 0 to 75 weight % fiber made of polyester, nylon, rayon, lyocell, cellulose, wool, silk, linen, bamboo, m-aramid, p-aramid, modacrylic, novoloid, melamine, regenerated cellulose, polyvinyl chloride, antistatic fiber, poly(p-phenylene benzobisoxazole) (PBO), polybenzimidazole (PBI), polysulphonamide (PSA), and combinations thereof, or other fibers not listed that are capable of being made into yarn and textile fabrics that are knit, woven, or nonwoven, and wherein the fabric has a weight from about 3 oz/yd2 to about 20 oz/yd2.
Abstract: The inventive ophthalmic composition comprises: (A) polyvinyl pyrrolidone K90; and (B) at least one selected from the group consisting of an oil component, a grease component and polyethylene glycol. The ophthalmic composition alleviates a sticky sensation to ensure an excellent use sensation.
Type:
Grant
Filed:
November 22, 2016
Date of Patent:
November 24, 2020
Assignee:
ROHTO PHARMACEUTICAL CO., LTD.
Inventors:
Aki Kiyomiya, Takahiro Kurose, Atsuko Nakata, Xiang Zheng
Abstract: Methods of sterilizing microparticles using a porous solid matrix which allows penetration of a sterilizing gas such as EtO to pass through are disclosed. The methods also include preparing a suspension of the sterilized microparticles by reconstituting the porous matrix containing the microparticles.
Abstract: The present invention provides an improved tissue adhesive to repair defects in soft tissue. Following ASTM standard tests, crosslinked methacryloyl-substituted gelatin hydrogels of the present invention (GelSEAL) were shown to exhibit adhesive properties, i.e. wound closure strength, shear resistance and burst pressure, that were superior to clinically used fibrin- and poly(ethylene glycol)-based glues. Chronic in vivo experiments in rats proved GelSEAL to effectively seal large lung leakages without additional sutures or staples, presenting improved performance as compared to fibrin and poly(ethylene glycol) glues. Furthermore, subcutaneous implantation in rats revealed high biocompatibility of GelSEAL as evidenced by low inflammatory host response.
Type:
Grant
Filed:
August 6, 2015
Date of Patent:
October 27, 2020
Assignee:
The Brigham and Women's Hospital, Inc.
Inventors:
Ali Khademhosseini, Nasim Annabi, Alexander Assmann
Abstract: To obtain a lifestyle-related disease therapeutic water which comprises a very small amount of anionized silver, nanosized gold, and 99.9% or more of water. A lifestyle-related disease therapeutic water comprising with respect to one liter of water (a), 3-15 mg in silver equivalent of thiosulfate silver ion (b), and 0.1-0.5 mg in gold equivalent of colloidal gold (c).
Type:
Grant
Filed:
December 9, 2016
Date of Patent:
October 13, 2020
Inventors:
Yoshio Ichikawa, Taro Shirakawa, Hitoshi Sato
Abstract: A colchicine-containing composition comprising colchicine as the active ingredient or colchicine in combination with pentoxifylline and tocopherol (Vitamin E) which are formulated for topical use in the prevention and treatment of radiation-induced fibrosis. And methods of making and administering the colchicine-containing compositions. The compositions can be used as topical applications for the prevention and treatment of radiation-induced fibrosis, commonly known as scarring, that can be debilitating, and can occur as a late and permanent complication of radiation therapy.
Abstract: Provided are a liposome composition in which an osmotic pressure of an inner water phase is 2-fold to 8-fold relative to the osmotic pressure of an outer water phase, and which encapsulates a water-soluble drug in a dissolved state, and also exhibits excellent preservation stability; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes obtained from lipids dissolved and emulsified in an organic solvent, each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which each of the liposomes encapsulates a water-soluble drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase; and a method for producing the same.
Type:
Grant
Filed:
March 30, 2017
Date of Patent:
September 15, 2020
Assignee:
FUJIFILM Corporation
Inventors:
Makoto Ono, Kohei Ono, Takeshi Matsumoto, Mikinaga Mori
Abstract: This disclosure provides adjuvant compositions that are capable of modulating the immune response in a subject. These adjuvant compositions may also be used enhance the immunogenicity of antigens. Also provided are methods of making the adjuvant compositions as well as methods of using the adjuvant compositions.
Abstract: A porous carbon material is provided. The porous carbon material having a value of specific surface area of at least 10 m2/g as measured by a nitrogen BET method, a pore volume of at least 0.1 cm3/g as measured by a BJH method and a MP method, and a R value of 1.5 or greater, wherein the R value is expressed as R=B/A, wherein A is an intensity at an intersection between a baseline of a diffraction peak of a (002) plane as obtained based on powdery X-ray diffractometry of the porous carbon material and a perpendicular line downwardly drawn from the diffraction peak of the (002) plane, and wherein B is an intensity of the diffraction peak of the (002) plane.
Abstract: Suggested are liquid cooling compositions, containing (a) L-Menthol, (b) D-Menthol, and (c) at least one further cooling agent, selected from the group consisting of isomenthol, menthyl acetate (L), menthyl acetate (D), menthyl acetate (iso), acetic acid menthyl lactate (iso) and acetic acid menthyl lactate (neo) with the proviso that in case that component (c) represents Isomenthol, the compositions do not contain any alkanediols.
Type:
Grant
Filed:
May 10, 2016
Date of Patent:
July 28, 2020
Assignee:
Symrise AG
Inventors:
Eike Doskotz, Thorsten Hielscher, Andreas Engelbrecht, Andrea Püttcher, Arnold Machinek
Abstract: By a process for producing a porous carbon material from a plant-derived material as a raw material, said process including carbonizing the plant-derived material at 800° C. to 1,400° C. and then applying a treatment with an acid or alkali, a porous carbon material having a value of specific surface area of at least 10 m2/g as measured by the nitrogen BET method, a silicon content of at most 1 wt % and a pore volume of at least 0.1 cm3/g is obtainable from a plant-derived material, which has a silicon content of at least 10 wt %, as a raw material. Also provided is a process for producing a porous carbon material equipped with excellent functionality so that the porous carbon material can be used, for example, as an anode material for batteries, an adsorbent, masks, adsorbing sheets, or carriers.
Abstract: Control or repellency of bed bugs is accomplished by bringing the bed bugs into contact with at least one of the compounds of the structure (I); wherein R is selected from —OH, —OC(O)R4, —OR6, —(OR6)2, wherein each R6 is independently selected from an alkyl group containing from 1 to 4 carbon atoms and R4 is a branched or straight chain saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; X is O or CH2, with the proviso that when X is O R can only be =0; each Z is independently selected from (CH) and (CH2) y is a numeral selected from 1 and 2; R1 is selected from H or a branched or straight chain saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms. R2 is selected from H and a branched or straight chain saturated or unsaturated hydrocarbyl group with zero to three double bonds and from 1 to 15 carbon atoms.
Abstract: A solid cosmetic composition includes a vegetable butter. The solid composition has dispersed therein gas bubbles, and the gas bubbles form at least 20% of the volume of the solid cosmetic composition.
Type:
Grant
Filed:
October 24, 2017
Date of Patent:
May 26, 2020
Assignee:
COSMETIC WARRIORS LIMITED
Inventors:
Helen Elizabeth Ambrosen, Margaret Joan Constantine, Mark Constantine